Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia

Biomaterials

Volumn 67, Issue , 2015, Pages 42-51

  Zhao, Nianxi ^a   Pei, Sung Nan ^a,e   Qi, Jianjun ^a   Zeng, Zihua ^a   Iyer, Swaminathan P ^b   Lin, Pei ^c   Tung, Ching Hsuan ^d   Zu, Youli ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Acute myeloid leukemia (AML); Aptamer drug conjugates; CD117 biomarker; Methotrexate (MTX); Oligonucleotide aptamer; Targeted therapy

Indexed keywords

BIOMARKERS; CELL DEATH; CHEMOTHERAPY; CYTOLOGY; DISEASES; DRUG THERAPY; OLIGONUCLEOTIDES; PATIENT TREATMENT; SYNTHESIS (CHEMICAL);

ACUTE MYELOID LEUKEMIA; APTAMERS; DRUG-CONJUGATES; METHOTREXATE (MTX); TARGETED THERAPY;

CELLS;

ANTIBODY CONJUGATE; APTAMER; GUANINE QUADRUPLEX; METHOTREXATE; SINGLE STRANDED DNA APTAMER METHOTREXATE CONJUGATE; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; SINGLE STRANDED DNA;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BINDING AFFINITY; BONE MARROW CELL; CANCER INHIBITION; CELL LYSATE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RECEPTOR BINDING; G1 PHASE CELL CYCLE CHECKPOINT; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; BONE MARROW; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; HUMAN; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; TUMOR CELL LINE;

APTAMERS, NUCLEOTIDE; BASE SEQUENCE; BONE MARROW; CELL LINE, TUMOR; CELL PROLIFERATION; DNA, SINGLE-STRANDED; HUMANS; LEUKEMIA, MYELOID, ACUTE; METHOTREXATE; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 84939634231     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.07.025     Document Type: Article

References (45)

1. Banerjee J., Nilsen-Hamilton M. Aptamers: multifunctional molecules for biomedical research. J. Mol. Med. 2013, 91(12):1333-1342.
2. Kanwar J.R., Shankaranarayanan J.S., Gurudevan S., Kanwar R.K. Aptamer-based therapeutics of the past, present and future: from the perspective of eye-related diseases. Drug Discov. Today 2014, 19(9):1309-1321.
3. Xing H., Hwang K., Li J., Torabi S.F., Lu Y. DNA aptamer technology for personalized medicine. Curr. Opin. Chem. Eng. 2014, 4:79-87.
4. Zhou J., Rossi J.J. Cell-type-specific, aptamer-functionalized agents for targeted disease therapy. Mol. Ther. Nucleic Acids 2014, 3:e169.
5. Hong B., Zu Y. Detecting circulating tumor cells: current challenges and new trends. Theranostics 2013, 3(6):377-394.
6. Li X., Zhao Q., Qiu L. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy. J. Control. Release Off. J. Control. Release Soc. 2013, 171(2):152-162.
7. Barbas A.S., Mi J., Clary B.M., White R.R. Aptamer applications for targeted cancer therapy. Future Oncol. 2010, 6(7):1117-1126.
8. Lassalle H.P., Marchal S., Guillemin F., Reinhard A., Bezdetnaya L. Aptamers as remarkable diagnostic and therapeutic agents in cancer treatment. Curr. Drug Metab. 2012, 13(8):1130-1144.
9. Pednekar P.P., Jadhav K.R., Kadam V.J. Aptamer-dendrimer bioconjugate: a nanotool for therapeutics, diagnosis, and imaging. Expert Opin. Drug Deliv. 2012, 9(10):1273-1288.
10. Radom F., Jurek P.M., Mazurek M.P., Otlewski J., Jelen F. Aptamers: molecules of great potential. Biotechnol. Adv. 2013, 31(8):1260-1274.
11. Zhao N., Pei S.N., Parekh P., Salazar E., Zu Y. Blocking interaction of viral gp120 and CD4-expressing T cells by single-stranded DNA aptamers. Int. J. Biochem. Cell Biol. 2014, 51:10-18.
12. Zhao N., You J., Zeng Z., Li C., Zu Y. An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells. Small 2013, 9(20):3477-3484.
13. Junutula J.R., Raab H., Clark S., Bhakta S., Leipold D.D., Weir S., Chen Y., Simpson M., Tsai S.P., Dennis M.S., et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 2008, 26(8):925-932.
14. Adem Y.T., Schwarz K.A., Duenas E., Patapoff T.W., Galush W.J., Esue O. Auristatin antibody drug conjugate physical instability and the role of drug payload. Bioconjugate Chem. 2014, 25(4):656-664.
15. Fauvel B., Yasri A. Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer. mAbs 2014, 6(4):838-851.
16. Sievers E.L., Senter P.D. Antibody-drug conjugates in cancer therapy. Annu. Rev. Med. 2013, 64:15-29.
17. Zeng Z., Zhang P., Zhao N., Sheehan A.M., Tung C.H., Chang C.C., Zu Y. Using oligonucleotide aptamer probes for immunostaining of formalin-fixed and paraffin-embedded tissues. Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc. 2010, 23(12):1553-1558.
18. Shigdar S., Lin J., Yu Y., Pastuovic M., Wei M., Duan W. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci. 2011, 102(5):991-998.
19. Mayer R.J., Davis R.B., Schiffer C.A., Berg D.T., Powell B.L., Schulman P., Omura G.A., Moore J.O., McIntyre O.R., Frei E. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer Leuk. Group B. N. Engl. J. Med. 1994, 331(14):896-903.
20. Burnett A.K. Treatment of acute myeloid leukemia: are we making progress?. Hematology Educ. Program Am. Soc. Hematol. Am. Soc. Hematol. Educ. Program 2012, 2012:1-6.
21. Klimek V.M. Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia. Curr. Opin. Hematol. 2013, 20(2):137-143.
22. Stone R.M. Consolidation chemotherapy for adults with AML in first remission: is there a best choice?. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2013, 31(17):2067-2069.
23. Martner A., Thoren F.B., Aurelius J., Hellstrand K. Immunotherapeutic strategies for relapse control in acute myeloid leukemia. Blood Rev. 2013, 27(5):209-216.
24. Peloquin G.L., Chen Y.B., Fathi A.T. The evolving landscape in the therapy of acute myeloid leukemia. Protein Cell 2013, 4(10):735-746.
25. Nazha A., Ravandi F. Acute myeloid leukemia in the elderly: do we know who should be treated and how?. Leuk. Lymphoma 2014, 55(5):979-987.
26. Ferrara F. Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?. Hematol. Oncol. 2014, 32(1):1-9.
27. Snauwaert S., Vandekerckhove B., Kerre T. Can immunotherapy specifically target acute myeloid leukemic stem cells?. Oncoimmunology 2013, 2(2):e22943.
28. Sweet K., Lancet J.E. Novel therapeutics in acute myeloid leukemia. Curr. Hematol. Malig. Rep. 2014, 9(2):109-117.
29. Li K., Lv X.X., Hua F., Lin H., Sun W., Cao W.B., Fu X.M., Xie J., Yu J.J., Li Z., et al. Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a toll-like receptor 2-mediated cell-penetrating peptide. Int. J. Cancer J. Int. du Cancer 2014, 134(3):692-702.
30. Konig H., Levis M. Is targeted therapy feasible in acute myelogenous leukemia?. Curr. Hematol. malignancy Rep. 2014, 9(2):118-127.
31. Walter R.B. The role of CD33 as therapeutic target in acute myeloid leukemia. Expert Opin. Ther. Targets 2014, 18(7):715-718.
32. Hans C.P., Finn W.G., Singleton T.P., Schnitzer B., Ross C.W. Usefulness of anti-CD117 in the flow cytometric analysis of acute leukemia. Am. J. Clin. Pathol. 2002, 117(2):301-305.
33. Doepfner K.T., Boller D., Arcaro A. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. Crit. Rev. Oncol./Hematol. 2007, 63(3):215-230.
34. Stirewalt D.L., Meshinchi S. Receptor tyrosine kinase alterations in AML - biology and therapy. Cancer Treat. Res. 2010, 145:85-108.
35. Marcucci G., Haferlach T., Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2011, 29(5):475-486.
36. Ashman L.K., Griffith R. Therapeutic targeting of c-KIT in cancer. Expert Opin. Invest. Drugs 2013, 22(1):103-115.
37. Liang J., Wu Y.L., Chen B.J., Zhang W., Tanaka Y., Sugiyama H. The C-kit receptor-mediated signal transduction and tumor-related diseases. Int. J. Biol. Sci. 2013, 9(5):435-443.
38. Zhang Y., Chen Y., Han D., Ocsoy I., Tan W. Aptamers selected by cell-SELEX for application in cancer studies. Bioanalysis 2010, 2(5):907-918.
39. Renaud de la Faverie A., Guedin A., Bedrat A., Yatsunyk L.A., Mergny J.L. Thioflavin T as a fluorescence light-up probe for G4 formation. Nucleic Acids Res. 2014, 42(8):e65.
40. Parekh P., Kamble S., Zhao N., Zeng Z., Portier B.P., Zu Y. Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer. Biomaterials 2013, 34(35):8909-8917.
41. Ackland S.P., Schilsky R.L. High-dose methotrexate: a critical reappraisal. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1987, 5(12):2017-2031.
42. Widemann B.C., Adamson P.C. Understanding and managing methotrexate nephrotoxicity. oncologist 2006, 11(6):694-703.
43. Buchen S., Ngampolo D., Melton R.G., Hasan C., Zoubek A., Henze G., Bode U., Fleischhack G. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br. J. Cancer 2005, 92(3):480-487.
44. Bruno J.G. A review of therapeutic aptamer conjugates with emphasis on new approaches. Pharmaceuticals 2013, 6(3):340-357.
45. Estevez M.C., Huang Y.F., Kang H., O'Donoghue M.B., Bamrungsap S., Yan J., Chen X., Tan W. Nanoparticle-aptamer conjugates for cancer cell targeting and detection. Methods Mol. Biol. 2010, 624:235-248.